ClinicalTrials.gg
CompletedNCT03353051NeoInnateUpdated Feb 24, 2020

Iron and Infection: Neonatal Nutritional Immunity

An observational study in Neonatal Infection and Nutritional Anemia, sponsored by London School of Hygiene and Tropical Medicine. Completed at 1 site in Gambia. Open to participants aged 5 Minutes to 28 Days. Per ClinicalTrials.gov, last updated 2020-02-24.

Sponsored by London School of Hygiene and Tropical Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
430
Ages
5 Minutes to 28 Days
Sex
All
01

Study summary

The motivation for this study was produced from our preliminary data, which showed that during the first 96 hours of life a full-term neonate will actively reduce the overall serum iron concentration of their blood and the transferrin saturation decreases rapidly from 45% in cord blood to \~20% by six hours post-delivery.

The Investigators hypothesise that this active sequestration of iron, which results in hypoferremia, is done in an effort to limit susceptibility to infection, a process referred to as nutritional immunity.

Currently, little is known about iron regulation and iron homeostasis during the first week of life and even less is known about the comparisons of nutritional immunity between full term, preterm and low birth weight neonates. Additionally, limited research has been conducted on the impact of these processes on bacterial pathogens.

In an effort to study the neonatal nutritional immunity and its role in neonatal susceptibility to infection, The investigator will conduct an observational study in full-term, preterm and low birth weight vaginally-delivered neonates born at Serrekunda General Hospital, The Gambia.

The investigators will fully characterise and quantify nutritional immunity during the early neonatal period and the investogators will assess how this impacts bacterial growth. Study sensitisation will occur at the antenatal clinic, during the mother's second trimester of pregnancy. Mothers will be consented and enrolled at delivery. Blood samples will be collected once from the umbilical cord and at serial time points from the neonates over the first week of life.

Read the detailed description

The epicentres of neonatal death worldwide are West and Central Africa, with an estimated 35 deaths per 1000 births. Neonatal infection is the third largest cause of death in children under five worldwide and is an ongoing major global public health challenge (WHO Millennium Development Goal 4). Intrauterine and neonatal infections have a high risk of causing substantial long-term neurological morbidity, affecting not just the individual but the local community and national productivity. Current research on neonatal sepsis in low-resource settings is focused on the use of mass perinatal antibiotic therapy for both mothers and babies. However, antibiotic resistance in the developing world is dramatically increasing and ablation of the neonatal microbiome has been linked with long-term health consequences. Novel therapeutic solutions are urgently required.

Nutritional immunity is the process by which the host innate immune system limits nutrient availability to invading organisms. Iron is an essential micronutrient for both microbial pathogens and their mammalian hosts. Changes in iron availability and distribution have significant effects on pathogen virulence and on the immune response to infection. Commonly found in blood, iron and its moieties (heme) are sequestered mainly in chaperone molecules (transferrin, lactoferrin, haptoglobin, hemopexin). The long-term goal of our research is to develop an anti-virulence therapeutic strategy that will augment nutritional immunity in the at-risk newborn, in order to improve neonatal survival, while avoiding the use of traditional empirical antibiotics.

During the dynamic neonatal period there are significant changes in circulation, oxygenation and iron homeostasis, the foetus maintains a high haematocrit to facilitate perfusion in utero. Within the first week of life, the neonate's haematocrit decreases as the RBCs containing foetal haemoglobin are broken down. Our preliminary data shows that during the first 24 hours of life full-term neonates will actively reduce the overall serum iron concentration and transferrin saturation decreases rapidly from 45% in cord blood to \~20% by six hours post-delivery.

Currently, little is known about nutritional immunity in the neonates or about its impact on bacterial pathogens. In the aims below, the investigators will investigate the hypothesis that nutritional immunity may be an evolutionary mechanism designed to protect neonates from infection during the first critical days of life, by limiting the pathogenicity and virulence of these organisms by reducing the availability of iron. The investigators hypothesize that this protective mechanism may not be activated in preterm and low birth weight neonates, putting these babies at an enhanced risk of neonatal infection.

Host chaperoned or unchaperoned iron, hemoglobin and heme in the blood can provide a growth-limiting nutrient to bacterial pathogens depending on the specific bacterial species and their iron-uptake mechanisms. Bacterial co-evolution with the host has resulted in two main strategies to combat host nutritional immunity: (1) chelation of iron away from chaperone proteins with siderophores, and (2) direct uptake of hemoglobin and heme moieties. Previous research and preliminary experiments conducted by our group, using ex-vivo growth assays in adult serum, has shown that growth of a panel of neonatal pathogenic bacteria each decreases in response to decreasing transferrin saturation and increases in response to increasing hemoglobin concentration. In addition, the investigators have shown that the in vitro growth of standard laboratory strains of four important causes of early neonatal sepsis in the developing world (Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and Streptococcus agalactiae) is decreased in hypoferremic serum collected from full term neonates between 6-24 hours after birth compared to serum from the umbilical cord at birth.

In an effort to study neonatal nutritional immunity and its role in neonatal susceptibility to infection, the investigators will conduct an observational study in full-term (FT), preterm (PTB) and low birth weight (LBW) vaginally-delivered neonates born at Serrekunda Hospital in The Gambia. The investigators will fully characterize and quantify nutritional immunity during the early neonatal period (Research Question 1, Research Question 2 and Research Question 3) and the investigators will assess how it impacts bacterial growth using in vitro assays (Research Question 4). Mothers will be consented and enrolled at delivery. Blood samples will be collected once from the umbilical cord and at serial time points from the neonates (see sampling schema).

02

Conditions studied

  • Neonatal Infection
  • Nutritional Anemia

Browse trials for

03

In context

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

This study's enrollment of 430 is above the median of 270 across 368 observational studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Minutes to 28 Days
Sexes eligible
All
Sampling method
Probability sample

Study population

All neonates will be born at Serrekunda Hospital, The Gambia. New Ballard score is only measure used to evaluate gestational age

Preterm neonates with Low Birth Weight (PTB with LBW) (Group A): Neonates will not be recruited directly into this group. These medical stable neonates will weigh \<2500g and also be \<37 weeks of gestational age.

Preterm (PTB) neonates (Group B): Medical stable neonates between >32 and \<37 weeks' gestational age. PTB neonates will weigh >2500g.

Low Birth Weight (LBW) neonates (Group C): Medical stable neonates with weight equal to or >2000g and \<2500g. LBW neonates will have a gestational age of >32 weeks.

Full Term (FT) neonates (Group D1-D3): All healthy FT neonates will weigh ≥2500g with gestational age ≥37 weeks.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Low Birth Weight (LBW) neonates:

  • Medical stable neonates
  • Neonatal weight ≥2000g and \<2500g
  • Born at Serrekunda Hospital
  • Gestational age will be >37 weeks.
  • Born to mothers at least 18 years of age

Preterm neonates with Low Birth Weight (PTB+LBW):

  • Medical stable neonates
  • Born at Serrekunda Hospital
  • Neonates weighing \<2500g and \<37 weeks of gestational age.
  • Born to mothers at least 18 years of age

Preterm (PTB) neonates:

  • Medical stable neonates
  • >32 and \<37 weeks' gestational age
  • Born at Serrekunda Hospital
  • PTB neonates will weigh more than 2500g
  • Born to mothers at least 18 years of age

Full Term (FT) neonates:

  • Healthy neonates
  • Born at Serrekunda Hospital
  • FT neonates will weigh ≥2500g
  • Gestational age ≥37 weeks
  • Born to mothers at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Major congenital malformations
  • Severe birth asphyxia
  • Children from multiple births
  • Medication (i.e. prophylactic antibiotics) given to neonate before first neonatal venous blood draw
  • Neonates born via Breech, Vacuum or C section
  • Neonates with infection/illness (information gained from venous bleed) will no longer be required to give future samples if originally required
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
430 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group A: other - observational study

    neonates ≥2000-\<2500g and born with a gestation age \<37 weeks.

    Other: Observational study

  • Group B: other- observational study

    Group B will contain neonates \>2500g and born with a gestation age \<37 weeks.

    Other: Observational study

  • Group C: other - observational study

    Group C will contain neonates ≥2000-\<2500g but with a gestation age \>37 weeks.

    Other: Observational study

  • Group D1:other - observational study

    Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.

    Other: Observational study

  • Group D2: other - observational study

    Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs

    Other: Observational study

  • Group D3: other - observational study

    Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.

    Other: Observational study

Interventions

  • OtherObservational study

    Observational study

06

What researchers measure

Primary outcomes

  1. serum iron

    will be measured using a COBAS INTEGRA 400 plus clinical chemistry analyzer

    Time frame: at 7 days after birth

Secondary outcomes

  1. TSAT (%) and heme iron (mg/dL)

    During the neonatal transition period in PTB and LBW neonates and FT babies in cord blood and at 6 hours after birth. TSAT and heme iron will be measured using a using a COBAS INTEGRA 400 plus clinical chemistry analyzer .

    Time frame: at 6 hours after birth

  2. Iron (ug/dL), TSAT (%) and heme iron (mg/dL) regulated regulation in FT neonates

    During the first 7 days of life. Iron, TSAT and heme iron will be measured using a using a COBAS INTEGRA 400 plus clinical chemistry analyzer

    Time frame: 7 days after birth

  3. microorganisms that are common causes of neonatal sepsis

    Does sera from PTB and LBW neonates after birth support more ex-vivo growth of microorganisms that are common causes of neonatal sepsis in Africa and The Gambia (Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Group B Streptococcus, Streptococcus pneumoniae and Salmonella Tyhpimurium) than sera from FT neonates

    Time frame: At 0, 6 and 24 hours after birth

07

Study locations

1 site
  • Serrekunda General Hospital
    Kanifing, Near Banjul, Gambia
08

References and documents

Publications

  • Cross JH, Jarjou O, Mohammed NI, Rayment Gomez S, Touray BJB, Prentice AM, Cerami C. Early postnatal hypoferremia in low birthweight and preterm babies: A prospective cohort study in hospital-delivered Gambian neonates. EBioMedicine. 2020 Feb;52:102613. doi: 10.1016/j.ebiom.2019.102613. Epub 2020 Jan 22. PubMed 31981986 ↗
  • Cross JH, Jarjou O, Mohammed NI, Prentice AM, Cerami C. Neonatal iron distribution and infection susceptibility in full term, preterm and low birthweight babies in urban Gambia: study protocol for an observational study. Gates Open Res. 2019 Oct 15;3:1469. doi: 10.12688/gatesopenres.12963.2. eCollection 2019. PubMed 31588425 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Nov 2018, 15 months.

Of 124 non-industry observational studies under Anemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's 15 months is below that.

Counting every sponsor, half of 145 studies reached it within 30 months; a quarter within 12 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2017
First posted
Nov 27, 2017
StartActual
Jul 25, 2017
Primary completionActual
Nov 21, 2018
CompletionActual
Apr 3, 2019
Last update
Feb 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03353051
Collaborators
University of Oxford, Department of State for Health and Social Welfare, The Gambia
Responsible party
Sponsor
First posted
Nov 27, 2017
Start date
Jul 25, 2017
Primary completion
Nov 21, 2018
Completion
Apr 3, 2019
Last update
Feb 24, 2020

Study contacts

Carla Cerami, MD, PhD
principal investigator · Medical Council Unit the Gambia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion